Skip to content
2000
Volume 18, Issue 6
  • ISSN: 1573-4137
  • E-ISSN: 1875-6786

Abstract

Background: The spread of new coronavirus 2019, the causative agent of viral pneumonia documented in Wuhan, brought a recent public health crisis globally. The best solution to overcome this pandemic is developing suitable and effective vaccines and therapeutics. However, discovering and creating a new drug is a lengthy process requiring rigorous testing and validation. Objective: Despite many newly discovered and old repurposed COVID-19 drugs under clinical trial, more emphasis should be given to research on COVID-19 NPs-based medicines, which could improve the efficacy of antiviral drugs to reduce their side effects. The use of NPs as carriers can reduce the frequency and duration of drug ingestion, enhance approved antiviral therapeutics' effectiveness, and overcome their limitations, such as low bioavailability. Besides, they can play a crucial role in fighting against the COVID-19 pandemic. In this regard, nanotechnology provides opportunities to develop new strategies for preventing, diagnosing, and treating COVID-19. Conclusion: This review highlighted the importance of NMs-based technical solutions in antiviral drugs for testing against the SARS-CoV-2 virus emergencies in the form of nanotherapeutics.

Loading

Article metrics loading...

/content/journals/cnano/10.2174/1573413717666211117150153
2022-11-01
2024-11-14
Loading full text...

Full text loading...

/content/journals/cnano/10.2174/1573413717666211117150153
Loading

  • Article Type:
    Review Article
Keyword(s): antiviral agent; chloroquine; clinical trial; COVID-19; nanoparticles; nanotherapy; siRNA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test